Immune profiling in residual disease: refining risk stratification after neoadjuvant therapy in HER2-positive breast cancer
- DOI
- 10.21037/tcr-2025-1-2880
- Published
- 2026-03
- Container
- Translational Cancer Research
- Publisher
- AME Publishing Company
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.21037/tcr-2025-1-2880,
title = {Immune profiling in residual disease: refining risk stratification after neoadjuvant therapy in HER2-positive breast cancer},
author = {Marcelo Antonini and André Mattar and Francisco Pimentel Cavalcante and Felipe Zerwes and Eduardo Camargo Millen and Fabricio Palermo Brenelli and Antonio Luis Frasson},
year = {2026},
journal = {Translational Cancer Research},
doi = {10.21037/tcr-2025-1-2880},
url = {https://doi.org/10.21037/tcr-2025-1-2880}
}RIS
TY - JOUR TI - Immune profiling in residual disease: refining risk stratification after neoadjuvant therapy in HER2-positive breast cancer AU - Marcelo Antonini AU - André Mattar AU - Francisco Pimentel Cavalcante AU - Felipe Zerwes AU - Eduardo Camargo Millen AU - Fabricio Palermo Brenelli AU - Antonio Luis Frasson PY - 2026 JO - Translational Cancer Research DO - 10.21037/tcr-2025-1-2880 UR - https://doi.org/10.21037/tcr-2025-1-2880 ER -
APA
Antonini, M., Mattar, A., Cavalcante, F. P., Zerwes, F., Millen, E. C., Brenelli, F. P., & Frasson, A. L. (2026). Immune profiling in residual disease: refining risk stratification after neoadjuvant therapy in HER2-positive breast cancer. Translational Cancer Research. https://doi.org/10.21037/tcr-2025-1-2880
Source records
- crossref · retrieved 2026-09-25T21:26:03.187Z